Compare ANNX & CCSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | CCSI |
|---|---|---|
| Founded | 2011 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.1M | 684.3M |
| IPO Year | 2020 | 2022 |
| Metric | ANNX | CCSI |
|---|---|---|
| Price | $3.49 | $40.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | $17.00 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 3.4M | 110.2K |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 3.88 |
| Revenue | N/A | ★ $349,696,000.00 |
| Revenue This Year | N/A | $3.40 |
| Revenue Next Year | N/A | $4.22 |
| P/E Ratio | ★ N/A | $10.45 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.36 | $20.20 |
| 52 Week High | $7.18 | $45.68 |
| Indicator | ANNX | CCSI |
|---|---|---|
| Relative Strength Index (RSI) | 36.30 | 55.90 |
| Support Level | N/A | $33.37 |
| Resistance Level | $4.42 | $41.19 |
| Average True Range (ATR) | 0.28 | 2.18 |
| MACD | -0.06 | 0.13 |
| Stochastic Oscillator | 10.82 | 57.20 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in the fax cloud business. The company's offerings include communication, data extraction, and digital signature solutions that enable users to securely access, exchange, and manage information across organizational and geographic boundaries. It serves multiple industry verticals, including healthcare, government, financial services, legal, and education. Geographically, the company operates in the United States, Canada, Ireland, and other countries. It derives the maximum revenue from the United States.